van der Laken C J, Boerman O C, Oyen W J, van de Ven M T, Edwards D S, Barrett J A, van der Meer J W, Corstens F H
Department of Nuclear Medicine, University Hospital Nijmegen, The Netherlands.
J Nucl Med. 1997 Aug;38(8):1310-5.
Chemotactic peptides have been proposed as vehicles to image infection and inflammation. Previous studies have shown high uptake at the site of infection soon after injection, most likely because of specific binding to receptors on locally present leukocytes. To investigate this hypothesis, the in vivo behavior of a synthetic chemotactic peptide was compared to a control peptide of similar molecular weight with low receptor binding affinity. In addition, the potential to target to different infections and sterile inflammation was tested.
Twenty-four hours after induction of Escherichia coli, Staphylococcus aureus and zymosan abscesses, rabbits were i.v. injected with either 1 mCi of 99mTc-labeled formyl-methionyl-leucyl-phenylalanyl-lysine-hydrazinonicotinamid e (99mTc-fMLFK-HYNIC) or 99mTc-labeled hydrazinonicotinamide-methionyl-leucyl-phenylalanyl-OMe (99mTc-HYNIC-MLFOMe, control peptide). Gamma camera images were obtained at 5 min and 1, 4, 8 and 20 hr postinjection. Biodistribution was determined at 20 hr postinjection.
The blood clearances of 99mTc-fMLFK-HYNIC and 99mTc-HYNIC-MLFOMe were similar. With time, 99mTc-fMLFK-HYNIC was retained in the abscess (E. coli), whereas the control agent 99mTc-HYNIC-MLFOMe was cleared from the abscess (0.049 +/- 0.011 versus 0.005 +/- 0.0003% 1D/g at 20 hr postinjection; p < 0.0005). Abscess-to-contralateral muscle ratios of 99mTc-fMLFK-HYNIC rose to 36.8 +/- 4.3 at 20 hr postinjection. E. coli, S. aureus and zymosan abscesses were clearly visualized from 4 hr postinjection onward. Abscess-to-background ratios increased to values varying from 4.4 +/- 0.2 (zymosan) to 7.1 +/- 0.6 (S. aureus) at 20 hr postinjection. The uptake in S. aureus and zymosan abscesses did not differ significantly from the uptake in E. coli abscesses.
fMLFK-HYNIC is retained in both acute infection and sterile inflammation by means of specific receptor binding if sufficient cellular infiltration is present.
趋化肽已被提议作为成像感染和炎症的载体。先前的研究表明,注射后不久感染部位就有高摄取,这很可能是由于与局部存在的白细胞上的受体特异性结合。为了研究这一假设,将一种合成趋化肽的体内行为与一种分子量相似但受体结合亲和力低的对照肽进行了比较。此外,还测试了靶向不同感染和无菌炎症的潜力。
在诱导大肠杆菌、金黄色葡萄球菌和酵母聚糖脓肿24小时后,给兔子静脉注射1毫居里的99mTc标记的甲酰甲硫氨酰亮氨酰苯丙氨酰赖氨酸肼烟酰胺(99mTc-fMLFK-HYNIC)或99mTc标记的肼烟酰胺甲硫氨酰亮氨酰苯丙氨酰-OMe(99mTc-HYNIC-MLFOMe,对照肽)。在注射后5分钟、1、4、8和20小时获得γ相机图像。在注射后20小时测定生物分布。
99mTc-fMLFK-HYNIC和99mTc-HYNIC-MLFOMe的血液清除率相似。随着时间的推移,99mTc-fMLFK-HYNIC保留在脓肿(大肠杆菌)中,而对照剂99mTc-HYNIC-MLFOMe从脓肿中清除(注射后20小时为0.049±0.011对0.005±0.0003%ID/g;p<0.0005)。99mTc-fMLFK-HYNIC的脓肿与对侧肌肉比值在注射后20小时升至36.8±4.3。从注射后4小时起,大肠杆菌、金黄色葡萄球菌和酵母聚糖脓肿都能清晰可见。注射后20小时,脓肿与背景比值增加到4.4±0.2(酵母聚糖)至7.1±0.6(金黄色葡萄球菌)不等的值。金黄色葡萄球菌和酵母聚糖脓肿中的摄取与大肠杆菌脓肿中的摄取没有显著差异。
如果存在足够的细胞浸润,fMLFK-HYNIC通过特异性受体结合保留在急性感染和无菌炎症中。